Zhang Xiaofei

Prof. Zhang Xiaofei


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2012 in Multidimensional Systems and Signal Processing
Verified
Journal Article
Closed access
PDF file
ZXZhang Xiaofei
Zhang Xiaofei
CCChen Chen
Chen Chen
JLJianfeng Li
Jianfeng Li
DXDazhuan Xu
Dazhuan Xu

1 January 2009 in Journal of Electromagnetic Waves and Applications
Verified
Journal Article
Closed access
ZXZhang Xiaofei
Zhang Xiaofei
XGX. Gao
X. Gao
WCW. Chen
W. Chen
In this paper, we address the problem of bind 2D Direction Of Arrival (DOA) estimation with L-shaped array. Based on shift invariance property, an improved method for estimating 2D DOA is presented...

12 June 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
QZQian Zhu
Qian Zhu
HHHu Hao
Hu Hao
DWDe-Sheng Weng
De-Sheng Weng
XZXiao-Fei Zhang
Xiao-Fei Zhang
CCChang-Long Chen
Chang-Long Chen
XJXia Jianchuan
Xia Jianchuan
The anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have been administered to patients with ALK-positive non-small cell lung cancer for a long period of time and show a promising response. However, the differences in the toxicity profiles among these drugs are still unclear. We performed a comprehensive search of the MEDLINE, EMBASE, WEB OF SCIENCE and COCHRANE databases from the drugs’ inception to May 2016 to identify clinical trials. Severe adverse events (AEs) (grade ≥ 3) based on the ALK-TKI type were analysed. Seventeen trials published between 2011 and 2016, including a total of 1826 patients, were eligible for analysis. Patients in 10 trials (n = 1000) received crizotinib, patients in 5 trials (n = 601) received ceritinib and patients in 2 trials (n = 225) received alectinib. The overall frequencies of treatment-related death and AEs due to treatment withdrawal were 0.9% (12/1365) and 5.5% (85/1543), respectively. Moreover, the frequency of severe AEs in patients treated with ceritinib was significantly higher than patients treated with crizotinib or alectinib, especially for hepatotoxicity, fatigue and some of gastrointestinal symptoms. Additionally, significant difference in the elevated lipase and amylase levels (grade ≥ 3) were detected between ceritinib and crizotinib/alectinib, whereas neutropenia was less frequent. ALK-TKIs were safe for ALK-positive patients. Moreover, statistically significant differences in some severe AEs among ceritinib, crizotinib and alectinib were detected in present study.

1 June 2018 in Aerospace Science and Technology
Verified
Journal Article
Closed access
KYKaikai Yu
Kaikai Yu
JXJinglei Xu
Jinglei Xu
SLShun Liu
Shun Liu
XZXiaofei Zhang
Xiaofei Zhang

30 September 2016 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Open access
PDF file
YZYong Zhang
Yong Zhang
JAJiao An
Jiao An
GYGuangyu Yang
Guangyu Yang
XZXiaofei Zhang
Xiaofei Zhang
YXYuan Xie
Yuan Xie
YFYan Feng
Yan Feng
Caldicellulosiruptor bescii is the most thermophilic cellulolytic species of organisms known to date. In our previous study, GH10 xylanase CbXyn10B from C. bescii displayed outstanding hydrolytic activity toward various xylans at high temperatures. To understand the structural basis for this protein's catalysis and thermostability, we solved the crystal structures of CbXyn10B and its complexes with xylooligosaccharides. These structural models were used to guide comparison with its mesophilic counterpart PbXyn10B. A distinctive structural feature is that thermophilic CbXyn10B presents a relatively stable interaction between the extended loops L7 and L8 in the catalytic cleft by an extensive hydrogen bonding network, which is mediated by Lys306, Arg314 and three well-ordered water molecules. Moreover, a unique aromatic cluster consisting of Try17, Phe20, Phe21, and Phe337 may enhance the interaction between the N- and C- terminus. Targeted mutagenesis demonstrated that these interactions substantially contribute to enzyme stabilization, as indicated by a considerable decrease in the melting temperature (Tm) of CbXyn10B by substituting critical residues with Ala. Therefore, it was shown that not only the aromatic interaction connecting protein termini but also the extensive hydrogen bonding network formed between surface loops could restrict the local structural flexibility and contribute significantly to the overall stability of enzymes. Furthermore, the xylooligosaccharides were found to tightly bind to the glycone subsites of xylanase, indicating higher affinities at these subsites and reflecting its substrate binding preference. Our results suggest that CbXyn10B is stabilized with distinct rigidity at the catalytic cleft as well as the terminal regions, which provides insights into the evolutionary strategy for accommodating the functional needs of GH10 enzymes to high temperature.

23 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CCChang-Long Chen
Chang-Long Chen
YWYing Wang
Ying Wang
QPQiu-Zhong Pan
Qiu-Zhong Pan
YTYan Tang
Yan Tang
QWQi-Jing Wang
Qi-Jing Wang
XJXia Jianchuan
Xia Jianchuan
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Chang-Long Chen1,2,*, Ying Wang1,3,*, Qiu-Zhong Pan1,2, Yan Tang1,2, Qi-Jing Wang2, Ke Pan1,2, Li-Xi Huang2, Jia He2, Jing-Jing Zhao1,2, Shan-Shan Jiang1,2, Xiao-Fei Zhang1,2, Hong-Xia Zhang1,2, Zi-Qi Zhou1,2, De-Sheng Weng1,2 and Jian-Chuan Xia1,2 1 Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China 2 Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China 3 Department of Epidemiology and Health Statistics, Guangdong Key Laboratory of Molecular Epidemiology, Guangdong Pharmaceutical University, Guangzhou, China * These authors have contributed equally to this work Correspondence to: Jian-Chuan Xia, email: // <![CDATA[ mail("xiajch","mail.sysu.edu",23,"") // ]]> De-Sheng Weng, email: // <![CDATA[ mail("wengdsh","sysucc.org",23,"") // ]]> Keywords: BRD7, tumor suppressor, hepatocellular carcinoma, prognosis, tumorigenicity Received: December 15, 2015 Accepted: February 08, 2016 Published: February 23, 2016